CN108947975B - 3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof - Google Patents
3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof Download PDFInfo
- Publication number
- CN108947975B CN108947975B CN201710350163.6A CN201710350163A CN108947975B CN 108947975 B CN108947975 B CN 108947975B CN 201710350163 A CN201710350163 A CN 201710350163A CN 108947975 B CN108947975 B CN 108947975B
- Authority
- CN
- China
- Prior art keywords
- piperazine
- indole
- methyl
- amino
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses (3S,6S) -3- (AA-amino-n-hexyl amido n-butyl) -6- (indole-3-ethyl) -piperazine-2, 5-diketone (in the formula, AA is L-Ala residue, Gly residue, L-Met residue, L-IIe residue, L-Pro residue, L-Val residue and L-Leu residue). Discloses a preparation method thereof, discloses the antitumor activity thereof, discloses the anti-tumor metastasis activity thereof and discloses the anti-inflammatory activity thereof, so that the invention discloses the application thereof in preparing antitumor drugs, anti-tumor metastasis drugs and anti-inflammatory drugs.
Description
Technical Field
The invention relates to (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-ethyl) -piperazine-2, 5-dione. To their preparation, to their antitumor activity, to their antitumor metastatic activity, and to their anti-inflammatory activity, and thus to their use in the preparation of antitumor, antitumor metastatic and anti-inflammatory drugs. The invention belongs to the field of biological medicine.
Background
Tumors seriously threaten the health of human beings. In addition to the poor prognosis of patients with tumors by themselves, metastasis associated with tumors further worsens the prognosis of patients. For example, more than 90% of patients with tumors die from metastases. Because the existing antitumor drugs have no effect of resisting tumor metastasis, the clinical curative effect of tumor chemotherapy is not ideal. The invention relates to a medicament for resisting tumor metastasis, which is an urgent clinical need. The inventors have previously disclosed that diketopiperazines of the four S, S-, R, R-, R, S-and S, R-configurations inhibit migration and invasion of HCCLM3 (highly metastatic human liver cancer cells) at a concentration of 0.5. mu.M. Later, the inventors further disclosed that R, R-configured diketopiperazines inhibited tumor metastasis to the lung in C57BL/6 mice at a dose of 5. mu. mol/kg. However, the lowest effective dose is 5. mu. mol/kg. To reduce the minimum effective dose, the inventors have developed various modifications to the butylamino group of the diketopiperazine in the S, S-configuration. After 3 years of exploration, the amino n-butyl of the diketopiperazine acylated with the amino n-hexanoic acid acylated with the amino acid with the fatty side chain (L-Ala, Gly, L-Met, L-IIe, L-Pro, L-Val and L-Leu) not only can reduce the minimum effective dose of anti-tumor metastasis to 0.5 mu mol/kg, but also can reduce the minimum effective dose of anti-tumor and anti-inflammatory to 0.5 mu mol/kg. The effective dose is reduced by 10 times, which shows that the structure modification has outstanding technical effect. Based on these findings, the inventors have proposed the present invention.
Disclosure of Invention
The first aspect of the present invention provides (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione of the formula (wherein AA is a L-Ala residue, a Gly residue, a L-Met residue, a L-IIe residue, a L-Pro residue, a L-Val residue and a L-Leu residue).
In a second aspect of the present invention, there is provided a process for the synthesis of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (wherein AA is a L-Ala residue, Gly residue, L-Met residue, L-IIe residue, L-Pro residue, L-Val residue and L-Leu residue), which comprises:
(1) condensing L-Boc-Lys (Cbz) and L-Trp-OBzl to obtain Boc-Lys (Cbz) -Trp-OBzl;
(2) Boc-Lys (Cbz) -Trp-OBzl is subjected to Boc removal in an ethyl acetate solution of hydrogen chloride to obtain Lys (Cbz) -Trp-OBzl;
(3) lys (Cbz) -Trp-OBzl is cyclized in 5% sodium bicarbonate water solution to generate (3S,6S) -3- (benzyloxycarbonylamino n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (1);
(4) hydrogenolysis of compound 1 to remove benzyloxycarbonyl to give (3S,6S) -3- (butylamino) -6- (indole-3-methyl) -piperazine-2, 5-dione (2);
(5) condensing the compound 2 and Boc-amino n-hexanoic acid to obtain (3S,6S) -3- (Boc-amino n-hexanoylamino n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (3);
(6) the compound 3 is subjected to Boc removal in an ethyl acetate solution of hydrogen chloride to obtain (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-diketone (4);
(7) and condensing the compound 4 with Boc-AA (AA is L-Phe residue, L-Tyr residue and L-Trp residue) to obtain (3S,6S) -3- (Boc-AA-amino n-hexylamido n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-diketone (5 a-g).
(8) Boc removal of compound 5a-g in hydrogen chloride in ethyl acetate solution gave (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6 a-g).
In a third aspect of the present invention, (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (wherein AA is L-Ala residue, Gly residue, L-Met residue, L-IIe residue, L-Pro residue, L-Val residue and L-Leu residue) was evaluated for its ability to inhibit the metastasis of lung cancer in C57BL/6 mice.
A fourth aspect of the present invention is to evaluate the inhibition of inflammation in ICR mice by (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (wherein AA is a L-Ala residue, Gly residue, L-Met residue, L-IIe residue, L-Pro residue, L-Val residue, and L-Leu residue).
A fifth aspect of the present invention is to evaluate the use of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (wherein AA is L-Ala residue, Gly residue, L-Met residue, L-IIe residue, L-Pro residue, L-Val residue, and L-Leu residue) for inhibiting tumor growth in S180 mice.
Drawings
FIG. 1 is a synthetic route for (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6a-c) AA in 5a and 6a is the L-Ala residue; AA in 5b and 6b is Gly residue; AA in 5c and 6c is L-Met residue; AA in 5d and 6d is L-IIe residue; AA in 5e and 6e is L-Pro residue; AA in 5f and 6f is L-Val residue; AA in 5g and 6g is L-Leu residue; i) dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), N-methylmorpholine (NMM), Tetrahydrofuran (THF); ii) a solution of hydrogen chloride in ethyl acetate; iii) ethyl acetate, 5% sodium bicarbonate; iv) Dimethylformamide (DMF), Pd/C, H2。
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of Boc-Lys (Cbz) -Trp-OBzl
7.7g (20mmol) of Boc-Lys (Cbz) was suspended in 100mL of anhydrous Tetrahydrofuran (THF), and 2.7g (20mmol) of 1-hydroxybenzotriazole (HOBt) and 5.0g (25mmol) of Dicyclohexylcarbodiimide (DCC) were added to the suspension in this order under ice bath, followed by stirring for 30 min. Thereafter, 8.0g (25mmol) of Trp-OBzl was added. The reaction mixture was adjusted to pH 9 by dropwise addition of N-methylmorpholine (NMM). The reaction mixture was stirred first for 1h on ice and then for 12h at room temperature. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was dissolved in 150mL of ethyl acetate solution. The ethyl acetate solution obtained was successively treated with 5% KHSO4The aqueous solution was washed 3 times, and the saturated NaCl aqueous solution was washed 3 times. Anhydrous Na for ethyl acetate layer2SO4Drying for 12h, filtering, and concentrating the filtrate under reduced pressure to dryness. The resulting yellow syrup was purified by silica gel column Chromatography (CH)2Cl2/CH3OH,100:1) 12.1g (88%) of the title compound are obtained as a colorless solid. ESI-MS (M/e):657[ M + H]+。
EXAMPLE 2 preparation of Lys (Cbz) -Trp-OBzl
Slowly mix in an ice bath with 3.8g (5mmol) Boc-Lys (Cbz) -Trp-OBzl and 52mL of ethyl acetate hydrogen chloride with stirring. The resulting solution was stirred in an ice bath for 5 h. After that, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 50mL of anhydrous ethyl acetate, and the resulting solution was concentrated under reduced pressure. This operation was repeated three times. The residue was washed thoroughly with anhydrous ether to give 3.45g (92%) of the title compound as a yellow powder. ESI-MS (M/e):557[ M + H ]]+。
EXAMPLE 3 preparation of (3S,6S) -3- (benzyloxycarbonyl butylamino) -6- (indole-3-methyl) -piperazine-2, 5-dione (1)
3.45g (6.2mmol) Lys (Cbz) -Trp-OBzl were dissolved in 150mL ethyl acetate. After the resulting solution was washed three times with a 5% aqueous solution of sodium hydrogencarbonate, the ethyl acetate solution was stirred at room temperature for 12 hours to sufficiently precipitate a colorless solid. 1.9g (55%) of the title compound are filtered off. ESI-MS (M/e):449[ M + H ]]+。
EXAMPLE 4 preparation of (3S,6S) -3-butylamino-6- (indole-3-methyl) -piperazine-2, 5-dione (2)
To a solution of 1.9g (4.2mmol) of (3S,6S) -3- (benzyloxycarbonyl butylamino) -6- (indole-3-methyl) -piperazine-2, 5-dione (1) in 20mL of anhydrous N, N-Dimethylformamide (DMF) was added 200mg of Pd/C, and H was introduced2The reaction was stirred at room temperature for 48 h. Pd/C was filtered off, and the filtrate was concentrated under reduced pressure to give 1.1g (83%) of the title compound as a white powder. ESI-MS (m/e): 315[ M + H ]]+。
EXAMPLE 5 preparation of Boc-amino-n-hexanoic acid
Add 5.23g (Boc) to a solution of 2.62g (20mmol) amino-n-hexanoic acid in 30mL distilled water2O and 30mL of dioxane, and the pH of the resulting reaction solution was adjusted to 9 with a 2N NaOH aqueous solution. Stirring at room temperature for 24h, and continuously reducing the pressure and exhausting gas in the period. KHSO for the reaction compound4Adjusting the pH value of the aqueous solution to 7, and removing dioxane by decompression and concentration. The remaining solution was further treated with KHSO4The pH was adjusted to 2. The remaining solution was extracted with 100mL ethyl acetate and anhydrous NaSO4Drying for 8 h. Filtration and concentration of the filtrate under reduced pressure gave 4.36g (94%) of the title compound. ESI-MS (M/e):232[ M + H]+。
EXAMPLE 6 preparation of (3S,6S) -3- (Boc-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (3)
From 0.97g (4.2mmol) Boc-amino-n-hexanoic acid and 1.9g (3.5mmol) (3S,6S) -3-aminon-butyl-6- (indole-3-methyl) -piperazine-2, 5-dione (2) 2.21g (71%) of the title compound were obtained as colorless solid using the method of example 1. ESI-MS (M/e):528[ M + H]+.1H-NMR(300MHz,DMSO-d6):/ppm＝10.865(s,1H),8.018(s,1H),7.918(s,3H),7.586(m,2H),7.313(d,J＝8.1Hz,1H),7.042(m,2H),6.952(m,1H),6.744(s,1H),4.109(m,1H),3.640(m,1H),3.228(m,1H),3.031(m,1H),2.891(m,2H),2.745(m,2H),2.004(t,J＝7.2Hz,2H),1.575(m,2H),1.431(m,10H),1.118(m,3H),0.970(m,3H),0.612(m,3H)。
EXAMPLE 7 preparation of (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4)
From 2.21g (4mmol) (3S,6S) -3- (Boc-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (3) 1.45g (82%) of the title compound was obtained as a colourless powder using the method of example 3. ESI-MS (M/z):428[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.947(s,1H),8.056(s,1H),7.936(s,3H),7.664(s,1H),7.598(d,J＝7.8Hz,1H),7.314(d,J＝8.1Hz,1H),7.045(m,2H),6.906(m,1H),4.116(m,1H),3.507(m,1H),3.267(m,2H),3.059(m,1H),2.773(m,4H),2.067(t,J＝7.2Hz,2H),1.574-1.463(m,4H),1.290(m,2H),0.986(m,3H),0.601(m,3H)。
EXAMPLE 8 preparation of (3S,6S) -3- (Boc-Ala-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5a)
From 679mg (3.6mmol) of Boc-Phe and 1280mg (3mmol) of (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4) by the method of example 1, 820mg (45%) of the title compound are obtained as a colorless solid. ESI-MS (M/z):599[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.884(s,1H),8.037(s,1H),7.936(s,1H),7.749(m,1H),7.588(m,2H),7.314(d,J＝7.8Hz,1H),7.045(m,2H),6.952(m,1H),6.783(d,J＝8.4Hz,1H),4.111(m,1H),3.941(m,1H),3.769(m,1H),3.535(m,2H),3.219(m,1H),3.042(m,3H),2.768(m,2H),2.028(t,J＝7.2Hz,2H),1.583-1.486(m,3H),1.437(m,13H),1.225(m,3H),0.991(m,3H),0.877(m,6H),0.609(m,3H)。
EXAMPLE 9 preparation of (3S,6S) -3- (Boc-Gly-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5b)
From 629mg (3.6mmol) Boc-Gly and 1280mg (3mmol) (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione by the method of example 1, 780mg (44%) of the title compound are obtained as a colorless solid. ESI-MS (M/z):585[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.879(s,1H),8.048(m,1H),7.939(m,1H),7.722(m,1H),7.585(m,2H),7.309(d,J＝8.1Hz,1H),7.038(m,2H),6.923(m,2H),4.107(m,1H),3.488(m,3H),3.214(m,1H),3.036(m,3H),2.891(m,2H),2.027(t,J＝7.2Hz,2H),1.507(m,2H),1.434(m,10H),1.199(m,3H),0.981(m,3H),0.590(m,3H)。
EXAMPLE 10 preparation of (3S,6S) -3- (Boc-Met-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5c)
From 750mg (3.6mmol) Boc-Met and 1280mg (3mmol) (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4) 650mg (33%) of the title compound was obtained as a colorless solid using the method of example 1. ESI-MS (M/z):659[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.877(s,1H),8.036(s,1H),7.931(s,1H),7.587(m,2H),7.315(d,J＝7.8Hz,1H),7.045(m,2H),6.929(m,1H),6.73(m,1H),4.114(m,1H),3.502(m,1H),3.231(m,1H),3.043(m,1H),2.894(m,2H),2.006(t,J＝7.2Hz,2H),1.481(m,13H),1.267(m,2H),0.981(m,3H),0.613(m,3H)。
EXAMPLE 11 preparation of (3S,6S) -3- (Boc-Ile-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5d)
From 831mg (3.6mmol) of Boc-IIe and 1280mg (3mmol) of (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4) by the method of example 1, 955mg (52%) of the title compound are obtained as a colorless solid. ESI-MS (M/z):641[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.947(s,1H),8.519(m,1H),8.223(m,1H),8.047(s,1H),7.944(s,2H),7.658(m,1H),7.591(m,2H),7.321(m,1H),6.929(m,1H),4.113(m,1H),3.927(m,1H),3.6275(m,1H),3.277(m,1H),3.055(m,3H),2.773(m,2H),2.031(m,2H),1.810(s,1H),1.2.97(m,15H),1.138(m,3H),0.981(m,2H),0.907(m,4H),0.843(m,6H),0.621(m,3H)。
EXAMPLE 12 preparation of (3S,6S) -3- (Boc-Pro-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5e)
From 770mg (3.6mmol) Boc-Pro and 1280mg (3mmol) (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4) 1125mg (60%) of the title compound was obtained as colorless solid using the method of example 1. ESI-MS (M/z) 625[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.897(s,1H),8.057(m,1H),7.945(m,1H),7.814(m,1H),7.587(m,2H),7.311(m,1H),7.040(m,2H),6.927(m,1H),4.118(m,1H),4.001(m,1H),3.497(m,1H),3.179(m,2H),3.179(m,1H),3.023(m,4H),2.756(m,2H),2.088(m,3H),1.738(m,4H),1.461(m,3H),1.392-.325(m,13H),1.214(m,3H),0.936(m,3H),0.563(m,3H)。
EXAMPLE 13 preparation of (3S,6S) -3- (Boc-Val-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5f)
From 780mg (3.6mmol) Boc-Val and 1280mg (3mmol) (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4) 870mg (46%) of the title compound was obtained as colorless solid using the method of example 1. ESI-MS (M/z) 627[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.876(s,1H),8.037(m,1H),7.940(m,1H),7.814(m,1H),7.590(m,2H),7.315(d,J＝7.8Hz,1H),7.045(m,2H),6.927(m,1H),6.817(m,1H),4.118(s,1H),3.927(m,1H),3.642(s,1H),3.233(m,2H),3.079(m,3H),2.750(m,2H),2.590(m,5H),2.005(m,2H),1.896(m,1H),1.464(m,3H),1.379(m,10H),1.238(m,3H),0.970(m,3H),0.822(m,6H),0.611(m,3H)。
EXAMPLE 14 preparation of (3S,6S) -3- (Boc-Leu-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5g)
From 766mg (3.6mmol) Boc-Leu and 1280mg (3mmol) (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (4)915m using the method of example 1g (46%) of the title compound as a colorless solid. ESI-MS (M/z):641[ M + H]+.1H NMR(300MHz,DMSO-d6):/ppm＝10.884(s,1H),8.037(s,1H),7.936(s,1H),7.749(m,1H),7.588(m,2H),7.314(d,J＝7.8Hz,1H),7.045(m,2H),6.928(m,1H),6.783(m,1H),4.111(m,1H),3.927(m,1H),3.768(m,1H),3.532(m,1H),3.219(m,1H),3.029(m,3H),2.768(m,2H),2.005(t,J＝7.2Hz,2H),1.3(m,3H),1.373(m,13H),1.225(m,3H),0.971(m,3H),0.856(m,6H),0.624(m,3H)。
EXAMPLE 15 preparation of (3S,6S) -3- (Ala-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6a)
From 600mg (1mmol) (3S,6S) -3- (Boc-Ala-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5a) by the method of example 3 was obtained 335mg (71%) of the title compound as a colorless solid. ESI-MS (M/z):499[ M + H]+.Mp 159-160℃；[α]D 25-26.9(c ═ 0.1, methanol); IR (KBr, cm)-1):3226,3007,2931,1651,1548,1455,1327,1259,1098,1009,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.945(s,1H),8.477(s,1H),8.303(s,3H),8.061(s,1H),7.949(s,1H),7.657(s,1H),7.590(d,J＝7.5Hz,1H),7.319(d,J＝8.1Hz,1H),7.045(m,2H),6.951(m,1H),4.114(m,1H),3.797(m,1H),3.502(m,1H),3.277(m,1H),3.136-2.989(m,3H),2.766(m,2H),2.028(t,J＝7.5Hz,2H),1.477(m,7H),1.256(m,1H),0.973(m,3H),0.609(m,3H)。
EXAMPLE 16 preparation of (3S,6S) -3- (Gly-amino-n-hexanoylamino-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6b)
From 350mg (0.7mmol) (3S,6S) -3- (Boc-Gly-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5b) 214mg (73%) of the title compound were obtained as a colourless solid by the method of example 3. ESI-MS (M/z):485[ M + H]+.Mp 159-161℃；[α]D 25-34.4(c ═ 0.1, methanol); IR (KBr, cm)-1):3218,3077,2928,2861,1659,1556,1455,1328,1262,1094,1010,918,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.927(s,1H),8.393(s,1H),8.052(s,3H),7.947(s,1H),7.640(s,1H),7.590(d,J＝7.8Hz,1H),7.318(d,J＝8.1Hz,1H),7.027(m,2H),6.927(m,1H),4.114(m,1H),3.502(m,3H),3.276(m,1H),3.075(m,3H),2.769(m,2H),2.027(t,J＝7.2Hz,2H),1.502-1.397(m,4H),1.154(m,2H),0.989(m,3H),0.613(m,3H)。
EXAMPLE 17 preparation of (3S,6S) -3- (Met-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6c)
From 650mg (1.2mmol) of (3S,6S) -3- (Boc-Met-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5c) using the method of example 3, 490mg (90%) of the title compound are obtained as a colorless solid. ESI-MS (M/z):541[ M + H]+.Mp 171-173℃；[α]D 25-33.8(c ═ 0.1, methanol); IR (KBr, cm)-1):3307,3053,2934,1650,1455,1330,1097,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.947(s,1H),8.519(m,1H),8.223(s,3H),8.047(s,1H),7.944(s,1H),7.658(m,1H),7.591(d,J＝7.8Hz,1H),7.321(d,J＝7.8Hz,1H),7.046(m,2H),6.929(m,1H),4.113(m,1H),3.927(m,2H),3.277-3.164(m,2H),3.055-2.995(m,2H),2.773(m,2H),2.031(t,J＝6.9Hz,2H),1.810(s,1H),1.508-1.408(m,5H),1.342(m,2H),1.138(m,1H),0.981(m,3H),0.907-0.843(m,6H),0.621(m,3H)。
EXAMPLE 18 preparation of (3S,6S) -3- (Ile-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6d)
From 650mg (1.2mmol) of (3S,6S) -3- (Boc-Ile-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5d) using the method of example 3, 490mg (90%) of the title compound are obtained as a colourless solid. ESI-MS (M/z):541[ M + H]+.Mp 171-173℃；[α]D 25-33.8(c ═ 0.1, methanol); IR (KBr, cm)-1):3307,3053,2934,1650,1455,1330,1097,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.947(s,1H),8.519(m,1H),8.223(s,3H),8.047(s,1H),7.944(s,1H),7.658(m,1H),7.591(d,J＝7.8Hz,1H),7.321(d,J＝7.8Hz,1H),7.046(m,2H),6.929(m,1H),4.113(m,1H),3.927(m,2H),3.277-3.164(m,2H),3.055-2.995(m,2H),2.773(m,2H),2.031(t,J＝6.9Hz,2H),1.810(s,1H),1.508-1.408(m,5H),1.342(m,2H),1.138(m,1H),0.981(m,3H),0.907-0.843(m,6H),0.621(m,3H)。
EXAMPLE 19 preparation of (3S,6S) -3- (Pro-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6e)
From 628mg (1.2mmol) (3S,6S) -3- (Boc-Pro-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5e) was obtained 286mg (54%) of the title compound as a colourless solid using the method of example 3. ESI-MS (M/z) 525[ M + H]+.Mp 134-136℃；[α]D 25-15.2(c ═ 0.1, methanol); IR (KBr, cm)-1):3226,3078,2929,2929,1651,1551,1455,1327,1258,1096,1010,743.1H NMR(300MHz,DMSO-d6):/ppm＝10.929(s,1H),8.568(m,1H),8.045(m,2H),7.641(m,1H),7.641(d,J＝7.8Hz,1H),7.319(d,J＝7.8Hz,1H),7.024(m,2H),6.951(m,1H),4.116(m,2H),3.730(m,1H),3.277-2.988(m,7H),2.751(m,2H),2.496(m,1H),2.054(m,2H),1.712(m,3H),1.503-1.406(m,4H),1.257(m,2H),0.974(m,3H),0.613(m,3H)。
EXAMPLE 20 preparation of (3S,6S) -3- (Val-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6f)
From 630mg (1mmol) (3S,6S) -3- (Boc-Val-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5f) 338mg (66%) of the title compound were obtained as colorless solid by the method of example 3. ESI-MS (M/z):527[ M + H]+.Mp 169-172℃；[α]D 25-11.5(c ═ 0.1, methanol); IR (KBr, cm)-1):3219,3075,2929,1651,1556,1455,1328,1254,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.952(s,1H),8.559(t,J＝5.4Hz,1H),8.218(s,3H),8.055(m,1H),7.941(m,1H),7.679(d,J＝5.4Hz,1H),7.618(d,J＝8.1Hz,1H),7.319(d,J＝8.1Hz,1H),7.073-7.021(m,2H),6.998-6.902(m,1H),4.114(m,1H),3.557(m,2H),3.539-3.141(m,2H),3.079(m,2H),2.770(m,2H),2.054(m,3H),1.507-1.383(m,4H),1.247(m,2H),0.947(m,9H),0.643(m,3H)。
EXAMPLE 21 preparation of (3S,6S) -3- (Leu-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6g)
From 650mg (1mmol) (3S,6S) -3- (Boc-Leu-amino-n-hexanylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (5g) using the method of example 3, 305mg (56%) of the title compound are obtained as colorlessAnd (3) a solid. ESI-MS (M/z):541[ M + H]+.Mp 132-135℃；[α]D 25-26.4(c ═ 0.1, methanol); IR (KBr, cm)-1):3232,2931,2161,1650,1557,1456,1330,1097,742；1H NMR(300MHz,DMSO-d6):/ppm＝10.930(s,1H),8.575(m,1H),8.224(s,3H),8.043(s,1H),7.941(s,1H),7.640(m,1H),7.591(d,J＝7.8Hz,1H),7.320(d,J＝8.1Hz,1H),7.048(m,2H),6.929(m,1H),4.114(m,1H),3.927(m,1H),3.502(m,1H),3.276-3.008(m,4H),2.776(m,2H),2.030(t,J＝7.2Hz,2H),1.661-1.409(m,7H),1.267(m,2H),1.054(m,3H),0.981-0.901(m,6H),0.624(m,3H)。
EXAMPLE 22 determination of the anti-tumor metastasis Activity of Compounds 6a-g
The assay model was inoculated with Lewis mouse lung carcinoma cells (LLC, purchased from ATCC) in DMEM medium (containing 10% inactivated fetal bovine serum, 1X 10)5U/L penicillin and 100mg/L streptomycin), and the cells are enriched by passage every two days according to an adherent cell culture method. Digesting the cells when the cells are in good growth state and in logarithmic growth phase, and adjusting the cell density to 1 × 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Inbred C57BL/6 male mice (SPF grade, body weight 20. + -.2 g) were taken and left-handed mice fixed. The right anterior limb axillary skin of the mouse was disinfected with 75% ethanol. The LLC tumor cell suspension is injected subcutaneously into the axilla of a mouse with a 1mL sterile syringe held in the right hand, and 0.2mL is injected into each mouse. After the mice are inoculated for 10 days, tumors with the diameter of about 4-5mm grow out, namely the tumor source. The Lewis lung cancer tumor-bearing mice are inoculated for 10 days and anesthetized by ether, and then the cervical vertebrae are removed for killing. Soaking in 75% ethanol for 10min, sterilizing, and removing tumor on clean bench. Well-grown tumor tissue was selected, minced in a sterile plate, and placed in a tissue homogenizer made of glass. Adding physiological saline with the temperature of 4 ℃ according to the ratio of the tumor mass to the volume of the physiological saline of 1 to 3(g to mL), and lightly grinding to prepare the cell suspension. The cell suspension is screened by 200-mesh cells to prepare single cell suspension. Adjusting the cell density of the single cell suspension to 1.5X 10 with physiological saline7one/mL. Staining with placental blue to count viable cells>95 percent. Left-handed inbred C57BL/6 male mice were fixed and their right anterior limb axillary skin was disinfected with 75% ethanol. Right hand-held 1mL sterile syringeThe tumor cell suspension is injected subcutaneously into the axilla of a mouse, and each injection is 0.2 mL. 10 days after inoculation, the mice developed tumors of 4-5mm in diameter, and the inoculated mice were randomly grouped by the measured tumor volume. Each group had 12 mice. Mice on day 11 of tumor inoculation were orally administered either a normal saline solution of the putative antitumor metastatic peptide RGDS (dose of 20. mu. mol/kg/day) or a normal saline solution of compounds 6a-g (dose of 0.5. mu. mol/kg/day) or a normal saline solution of compound 4 (dose of 5. mu. mol/kg/day) or an oral normal saline (dose of 10 mL/kg/day) 1 dose per day for 12 consecutive days, and tumor volumes were measured and recorded every two days. The next day of the last administration, tumor volume was measured, cervical spine was removed by ether anesthesia and sacrificed, tumor of the mice was weighed, lung of the mice was taken and tumor nodules transferred from the lung of the tumor were counted. Statistical analysis of the data was performed using the t-test. The results are shown in Table 1. Compounds 6a-g were not only effective in inhibiting tumor lung metastasis at 0.5 μmol/kg dose, but also had no significant difference in activity from their 40-fold higher RGDS and 10-fold higher compound 4 doses. These data indicate that the present invention has significant technical effects.
Anti-metastatic Activity of Compounds 6a-g of Table 1
a) P <0.01 to saline, p >0.05 to RGDS and compound 4; n-12
EXAMPLE 23 determination of the anti-tumor growth Activity of Compounds 6a-g
Doxorubicin, compound 4 and compounds 6a-g were all dissolved in saline prior to assay for administration to S180 mice. Taking S180 ascites tumor liquid which is inoculated in a male ICR mouse and grows vigorously for 10 days in a sterile environment, diluting the S180 ascites tumor liquid into liquid (1:2) by using normal saline, fully mixing the liquid, dyeing the tumor cell suspension by using freshly prepared 0.2% trypan blue, uniformly mixing the liquid and the liquid, counting the liquid according to a white cell counting method, wherein the blue-dyed cell is a dead cell, and the non-dyed cell is a live cell. The cell concentration is 4-large-grid viable cell number/4 × 104The cell density was calculated as the x dilution factor ═ cell number/mL, and the cell viability ═ viable cell number-Cell viability was calculated as (number of live cells + number of dead cells) × 100%. Homogenizing tumor solution with survival rate of more than 90% to density of 2.0 × 107Cell suspension per mL. This cell suspension was inoculated subcutaneously (0.2 mL/mouse) in the right axilla of a mouse to prepare S180 tumor-bearing mice. 24h after inoculation, S180 tumor-bearing mice were intraperitoneally injected daily with a normal saline solution of doxorubicin (dose 2. mu. mol/kg/day g) or daily orally administered with a normal saline solution of Compound 4 (dose 5. mu. mol/kg/day) or daily orally administered with a normal saline solution of Compounds 6a-g (dose 0.5. mu. mol/kg/day). The administration is once daily for 12 days. The day after the last dose, tumor volume was measured, cervical spine was removed under ether anesthesia and sacrificed, then the right axillary tumor growth site of the mouse was fixed with forceps, and the skin was excised and the tumor was blunt-stripped and weighed. Efficacy was expressed as tumor weight (mean ± SD g), and data were analyzed by t-test and variance. The results are shown in Table 2. Compounds 6a-g were not only effective at 0.5 μmol/kg dose in inhibiting tumor growth, but also did not differ significantly from compound 4, which was 10-fold more active than them at the dose. These data indicate that the present invention has significant technical effects.
TABLE 2 Effect of Compounds 6a-g on tumor growth in S180 mice
a) P <0.05 to saline, p >0.05 to compound 4; b) p <0.01 to saline, p >0.05 to compound 4; n is 12.
EXAMPLE 24 determination of the anti-inflammatory Activity of Compounds 6a-g
Since xylene-induced ear swelling in mice is recognized as an acute inflammation model, the present invention measures the therapeutic effect of compounds 6a-g on a xylene-induced ear swelling model in mice. Because aspirin is a positive drug for treating acute inflammation, aspirin is selected as a positive control in the present invention. ICR male mice (body weight 42 + -3 g) were allowed to rest for 2 days at 22 deg.C, with free access to water and food. Thereafter, the mice were randomly divided into a saline group (dose of 0.2 mL/mouse), an aspirin group (dose of 1.11mmol/kg), a compound 4 group (dose of 5. mu. mol/kg) and a compound 6a-g group (dose of 0.5. mu. mol/kg), and 12 mice were each group. The mice were tested either orally with normal saline, orally with aspirin, orally with compound 4, or orally with compound 6a-g, as indicated. After 30min of administration, the left auricle of the mouse was evenly smeared with 30 μ L of xylene, and after 2h, the mouse was subjected to ether anesthesia, the neck was cut off, the left and right ears were cut off, round ears were taken at the same positions of the two ears by a 7mm punch, and the difference in swelling between the two ears was weighed and found to be the swelling degree. Namely the swelling degree is equal to the weight of the left ear disk to the weight of the right ear disk. Compounds 6a-g were not only effective at 0.5 μmol/kg dose in inhibiting xylene-induced ear swelling in mice, but also showed no significant difference in activity from compound 4 at a dose 10-fold higher than that of the other. These data indicate that the present invention has significant technical effects.
TABLE 3 Effect of Compounds 6a-g on xylene-induced ear swelling in mice
a) P <0.05 to saline, p >0.05 to compound 4; b) p <0.01 to saline and compound 4; n is 12.
Claims (5)
1. (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione of the formula, wherein AA is a L-Ala residue, a Gly residue, a L-Met residue, a L-IIe residue, a L-Pro residue, a L-Val residue and a L-Leu residue,
2. a process for the preparation of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione as claimed in claim 1, which comprises:
(1) condensing L-Boc-Lys (Cbz) and L-Trp-OBzl to obtain Boc-Lys (Cbz) -Trp-OBzl;
(2) Boc-Lys (Cbz) -Trp-OBzl is subjected to Boc removal in an ethyl acetate solution of hydrogen chloride to obtain Lys (Cbz) -Trp-OBzl;
(3) the ethyl acetate solution of Lys (Cbz) -Trp-OBzl is fully washed by 5 percent sodium bicarbonate water solution, and then cyclization is carried out to generate (3S,6S) -3- (benzyloxycarbonylamino n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (1);
(4) hydrogenolysis of compound 1 to remove benzyloxycarbonyl to give (3S,6S) -3- (butylamino) -6- (indole-3-methyl) -piperazine-2, 5-dione (2);
(5) condensing the compound 2 and Boc-amino n-hexanoic acid to obtain (3S,6S) -3- (Boc-amino n-hexanoylamino n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (3);
(6) the compound 3 is subjected to Boc removal in an ethyl acetate solution of hydrogen chloride to obtain (3S,6S) -3- (amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-diketone (4);
(7) condensing the compound 4 with Boc-AA to obtain (3S,6S) -3- (Boc-AA-amino n-hexylamido n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-diketone (5 a-g);
(8) boc removal of compound 5a-g in hydrogen chloride in ethyl acetate solution gave (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione (6 a-g).
3. Use of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione according to claim 1 for the preparation of a medicament against tumor metastasis.
4. Use of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione according to claim 1 for the preparation of an antitumor medicament.
5. Use of (3S,6S) -3- (AA-amino-n-hexylamido-n-butyl) -6- (indole-3-methyl) -piperazine-2, 5-dione according to claim 1 for the preparation of an anti-inflammatory medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710350163.6A CN108947975B (en) | 2017-05-18 | 2017-05-18 | 3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710350163.6A CN108947975B (en) | 2017-05-18 | 2017-05-18 | 3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108947975A CN108947975A (en) | 2018-12-07 |
| CN108947975B true CN108947975B (en) | 2020-11-27 |
Family
ID=64461827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710350163.6A Expired - Fee Related CN108947975B (en) | 2017-05-18 | 2017-05-18 | 3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108947975B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61112060A (en) * | 1984-11-02 | 1986-05-30 | Fujisawa Pharmaceut Co Ltd | Piperazine compound |
| CN105272980A (en) * | 2014-06-10 | 2016-01-27 | 首都医科大学 | (3R,12aS)-3-(4-aminobutyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, and preparation and application thereof |
| CN105294660A (en) * | 2014-06-10 | 2016-02-03 | 首都医科大学 | 3R, 6S-3, 6-disubstituted piperazine-2, 5-diketone, preparation therefor and application thereof |
| CN105503833A (en) * | 2014-10-20 | 2016-04-20 | 首都医科大学 | Indole piperazine dione compound, and preparation and treatment effect thereof |
-
2017
- 2017-05-18 CN CN201710350163.6A patent/CN108947975B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61112060A (en) * | 1984-11-02 | 1986-05-30 | Fujisawa Pharmaceut Co Ltd | Piperazine compound |
| CN105272980A (en) * | 2014-06-10 | 2016-01-27 | 首都医科大学 | (3R,12aS)-3-(4-aminobutyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, and preparation and application thereof |
| CN105294660A (en) * | 2014-06-10 | 2016-02-03 | 首都医科大学 | 3R, 6S-3, 6-disubstituted piperazine-2, 5-diketone, preparation therefor and application thereof |
| CN105503833A (en) * | 2014-10-20 | 2016-04-20 | 首都医科大学 | Indole piperazine dione compound, and preparation and treatment effect thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108947975A (en) | 2018-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108948137B (en) | 3S-indolylethyl-6S-polar amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof | |
| CN108947975B (en) | 3S-indolylethyl-6S-fatty amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof | |
| CN108929320B (en) | 3R-indolylmethyl-6R-oxazolidinone modified piperazine-2, 5-dione, synthesis, activity and application thereof | |
| CN108976201B (en) | 3R-indolylmethyl-6S-aromatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947976B (en) | 3S-indolylmethyl-6S-aromatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110577568B (en) | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis, activity and application thereof | |
| CN110577517B (en) | Methyl indole and aromatic amino acid modified 2, 5-diketopiperazine, synthesis, activity and application thereof | |
| CN110551108B (en) | 3R-indolylmethyl-6R-amino acid modified 2, 5-diketopiperazines, synthesis, activity and use thereof | |
| CN110577518B (en) | Methyl indole and amide side chain amino acid modified diketopiperazine, synthesis and application thereof | |
| CN108976203B (en) | 3S-indolylmethyl-6R-Lys modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947978B (en) | 3R-indolylmethyl-6R-Tyr modified piperazine-2, 5-diketone and synthesis, activity and application thereof | |
| CN108929313B (en) | 3R-indolylmethyl-6R-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108948141B (en) | 3R-indolylmethyl-6S-Pro modified piperazine-2, 5-dione, synthesis, activity and application thereof | |
| CN109456311B (en) | 3R-indolylmethyl-6R-aromatic amino acid modified piperazine-2, 5-diketone and synthesis, activity and application thereof | |
| CN108976202B (en) | 3R-indolylmethyl-6S-Lys modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108976277B (en) | 3R-indolylmethyl-6S-polar amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947977B (en) | Piperazine-2, 5-diketone modified by 3R-indolylmethyl-6R-amide side chain amino acid, and synthesis, activity and application thereof | |
| CN108976204B (en) | 3S-indolylmethyl-6R-aspartic acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110551174B (en) | Amino acid and tranexamic acid modified diketopiperazines, their preparation, activity and use | |
| CN108947981B (en) | 3R-indolylmethyl-6S-aliphatic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947980B (en) | 3R-indolylmethyl-6S-Thr modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN110551175B (en) | Amino acid and tranexamic acid modified diketopiperazine, preparation, activity and application thereof | |
| CN108929314B (en) | 3R-indolylmethyl-6S-acidic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108929369B (en) | 3R-indolylmethyl-6R-acidic amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof | |
| CN108947979B (en) | 3R-indolylmethyl-6R-polar amino acid modified piperazine-2, 5-dione, and synthesis, activity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201127 |